Intensity Therapeutics In... (INTS)
The price, the headline numbers and the latest news, in one place.
Intensity Therapeutics Inc. (INTS) Stock Price, Analysis & Data
| Bid | 3.17 |
| Market Cap | 14.04M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -11.16M |
| 3.03 | |
| -2 | |
| n/a | |
| -2.16 | |
| P/B (ttm) | 1.09 |
| P/S (ttm) | n/a |
| Earnings Date | Aug 7, 2025 |
| Ask | 5.5 |
| Volume | 22,422 |
| Avg. Volume (20D) | 45,079 |
| Open | 4.30 |
| Previous Close | 4.27 |
| Day's Range | 4.24 - 4.58 |
| 52-Week Range | 3.51 - 43.50 |
| Analyst | Strong Buy |
| Price Target | 17.5 (311.76%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About INTS
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorp...
Financial Performance
In 2025, Intensity Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -11.61M, a decrease of -28.66%.
Financial StatementsAnalyst Forecast
According to 6 analyst ratings, the average rating for INTS stock is "Strong Buy". The 12-month stock price forecast is 17.5, which is upside of 311.76% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -1.11 misses estimates by -0.34, with 79.82% YoY growth.
Analysts project revenue of ... Upgrade
